All In Biotech

Drug Trial Radar · NCT05502237

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,021 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,021

Actual

Start

Oct 12, 2022

Primary completion

Jun 2028

Study completion Jan 2029

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Arcus Biosciences, Inc.
First posted
Aug 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • ZimberelimabDrug

    Administered intravenously

  • DomvanalimabDrug

    Administered intravenously

  • PembrolizumabDrug

    Administered intravenously

  • CarboplatinDrug

    Administered intravenously

  • CisplatinDrug

    Administered intravenously

  • PaclitaxelDrug

    Administered intravenously

  • Nab-paclitaxelDrug

    Administered intravenously

  • PemetrexedDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in Participants With Positive Programmed Cell Death-Ligand 1 (PD-L1) Expression (≥1%Tumor Cells) and in all Randomized Participants.Time frame: Up to 68 months

Locations

186 sites in 23 countries. Site status is shown where the registry gives one.

  • Innovative Clinical Research Institute

    Whittier, California

  • George Washington Medical Faculty Associates

    Washington D.C., District of Columbia

  • Moffitt Cancer Center

    Tampa, Florida

  • Illinois Cancer Care

    Peoria, Illinois

  • Messino Cancer Centers

    Asheville, North Carolina

  • Oncology Hematology Care, Inc.

    Cincinnati, Ohio

  • Hematology & Oncology Associates

    Eugene, Oregon

  • AHN Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Texas Oncology - Austin

    Austin, Texas

  • Oncology and Hematology Associates of Southwest Virginia, Inc

    Blacksburg, Virginia

  • Northwest Cancer Specialists, PC

    Vancouver, Washington

  • Investigaciones CORI S.R.L.

    Capital, Argentina

  • Centro Médico Privado Centro de Especialidades Médicas Ambulatorias e Investigación Clínica

    Cardoba, Argentina

  • Sanatorio Allende

    Córdoba, Argentina

  • Sanatorio Britanico de Rosario

    Rosario, Argentina

  • Sanatorio Parque de Rosario

    Rosario, Argentina

  • Hospital Provincial del Centenario

    Rosario, Argentina

  • Instituto Medico de la Fundacion Estudios Clinicos

    Rosario, Argentina

  • Clínica Viedma

    Viedma, Argentina

  • Ordensklinikum Linz GmbH, Elisabethinen

    Linz, Austria

  • Krankenhaus Nord - Klinik Floridsdorf

    Vienna, Austria

  • Klinikum Wels-Grieskirchen

    Wels, Austria

  • Algemeen Ziekenhuis Sint-Lucas

    Aalst, Belgium

  • Grand Hopital de Charleroi asbl (GHdC)

    Charleroi, Belgium

  • AZ Sint-Maarten

    Mechelen, Belgium

  • CHU UCL Namur / Site Sainte Elisabeth

    Namur, Belgium

  • Cenantron Centro Avançado de Tratamento Oncologico Ltda

    Belo Horizonte, Brazil

  • Hospital Evangelico de Cachoeiro de Itapemirim

    Cachoeiro de Itapemirim, Brazil

  • Fundacao Universidade De Caxias Do Sul - FUCS/RS

    Caxias do Sul, Brazil

  • Instituto do Câncer do Ceará - ICC

    Fortaleza, Brazil

  • Oncosite - Centro de Pesquisa Clinica em Oncologia LTDA

    Ijuí, Brazil

  • Irmandade da Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Brazil

  • Hospital São Lucas da PUCRS

    Porto Alegre, Brazil

  • Hospital Ana Nery Santa Cruz do Sul

    Santa Cruz do Sul, Brazil

  • Instituto Brasiliero de Controle do Cancer IBCC

    São Paulo, Brazil

  • Centro Des Pesquisas Clinicas da Fundacao Doutor Amaral Carvalho

    São Paulo, Brazil

  • Centre Integre de sante et de services sociaux de la Monteregie Centre

    Greenfield Park, Canada

  • Moncton Hospital

    Moncton, Canada

  • CISSS des Laurentides

    Québec, Canada

Showing 40 of 186 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.